Medicine Supply Notification: Ranitidine all formulations – Update
- All preparations of ranitidine (tablets, effervescent tablets, oral solution and injection) are out of stock until further notice.
- Following recent advice from the EMA, the MHRA have suspended all licenses for ranitidine products.
Department of Health and Social Care (DHSC) has issued a medicine supply notification for Ranitidine (all formulations) .
- Ranitidine 50mg/2ml injection is anticipated to be unavailable from the end of May 2020 until further notice.
- Ranitidine film-coated tablets, effervescent tablets and oral solution continue to remain unavailable with no date for resupply.
- All formulations of Ranitidine are affected due to on-going regulatory investigations into the presence of the contaminant, N-nitrosodimethylamine (NDMA), in samples of Ranitidine active substance
- Clinical advice on alternatives of Ranitidine preparations for adults and children has been shared in the previous supply disruption alert SDA/2019/005 (U2)
A copy of this medicine supply notification has been sent to all pharmacy NHS email addresses.
The DHSC Medicine Supply Team provide a monthly update on potential supply issues affecting both primary and secondary care. This update has been uploaded to the Specialist Pharmacy Services (SPS) website (login required). To register, you will need an NHS email address. Once set up and logged in, you will be able to access it online.
New shortages not listed on the SPS website, can be reported using our shortage reporting tool.